{
 "disease": "vulvar-cancer",
 "label": "Vulvar cancer",
 "url": "https://usebiotransfer.org/disease/vulvar-cancer/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "483a2d1aaaca",
  "targets": "5a63a4555442"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "PIK3CA",
   "ensembl": "ENSG00000121879",
   "n_drug_entries": 32,
   "n_distinct_drugs": 31,
   "drugs": {
    "ALPELISIB": "APPROVAL",
    "APITOLISIB": "PHASE_2",
    "AZD-6482": "UNKNOWN",
    "BAY-1082439": "PHASE_1",
    "BGT-226": "PHASE_1_2",
    "BUPARLISIB": "PHASE_3",
    "COPANLISIB": "APPROVAL",
    "DACTOLISIB": "PHASE_3",
    "DS-7423": "PHASE_1",
    "FIMEPINOSTAT": "PHASE_2",
    "GEDATOLISIB": "PHASE_3",
    "GSK-1059615": "PHASE_1",
    "INAVOLISIB": "APPROVAL",
    "IZORLISIB": "PHASE_1_2",
    "OMIPALISIB": "PHASE_1",
    "PANULISIB": "PHASE_1",
    "PAXALISIB": "PHASE_2_3",
    "PF-04691502": "PHASE_2",
    "PICTILISIB": "PHASE_2",
    "PILARALISIB": "PHASE_2",
    "PKI-179": "PHASE_1",
    "RECILISIB": "PHASE_1",
    "SAMOTOLISIB": "PHASE_2",
    "SERABELISIB": "PHASE_2",
    "SF-1126": "PHASE_2",
    "SONOLISIB": "PHASE_2",
    "TASELISIB": "PHASE_3",
    "VOXTALISIB": "PHASE_2",
    "VS-5584": "PHASE_1",
    "WX-037": "PHASE_1",
    "ZSTK-474": "PHASE_1"
   },
   "approved": [
    "ALPELISIB",
    "COPANLISIB",
    "INAVOLISIB"
   ],
   "n_approved": 3,
   "approved_for": {
    "ALPELISIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "COPANLISIB": [
     "follicular lymphoma",
     "non-Hodgkin lymphoma",
     "neoplasm of mature B-cells"
    ],
    "INAVOLISIB": [
     "breast neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "HRAS",
   "ensembl": "ENSG00000174775",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "SALIRASIB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "NOTCH1",
   "ensembl": "ENSG00000148400",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BRONTICTUZUMAB": "PHASE_1"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "EGFR",
   "ensembl": "ENSG00000146648",
   "n_drug_entries": 82,
   "n_distinct_drugs": 74,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "AMIVANTAMAB": "APPROVAL",
    "AUMOLERTINIB": "APPROVAL",
    "AV-412": "PHASE_1",
    "AZD-3759": "PHASE_2_3",
    "AZD-4769": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BRIGATINIB": "APPROVAL",
    "CANERTINIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "CETUXIMAB": "APPROVAL",
    "CETUXIMAB SAROTALOCAN": "APPROVAL",
    "CLN-081": "PHASE_3",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DEPATUXIZUMAB": "PHASE_2",
    "DEPATUXIZUMAB MAFODOTIN": "PHASE_3",
    "DULIGOTUZUMAB": "PHASE_2",
    "EPITINIB": "PHASE_1",
    "ERLOTINIB": "APPROVAL",
    "FALNIDAMOL": "PHASE_1",
    "FIRMONERTINIB": "PHASE_3",
    "FUTUXIMAB": "PHASE_3",
    "GC1118": "PHASE_2",
    "GEFITINIB": "APPROVAL",
    "ICOTINIB": "APPROVAL",
    "IMGATUZUMAB": "PHASE_2",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "LAZERTINIB": "APPROVAL",
    "LOSATUXIZUMAB VEDOTIN": "PHASE_1",
    "MAB-425": "UNKNOWN",
    "MATUZUMAB": "PHASE_2",
    "MAVELERTINIB": "PHASE_1_2",
    "MDX-447": "PHASE_1",
    "MOBOCERTINIB": "APPROVAL",
    "MODOTUXIMAB": "PHASE_2",
    "NAQUOTINIB": "PHASE_3",
    "NAZARTINIB": "PHASE_3",
    "NECITUMUMAB": "APPROVAL",
    "NERATINIB": "APPROVAL",
    "NIMOTUZUMAB": "APPROVAL",
    "OLMUTINIB": "APPROVAL",
    "OSIMERTINIB": "APPROVAL",
    "PANITUMUMAB": "APPROVAL",
    "PELITINIB": "PHASE_2",
    "PF-06459988": "PHASE_2",
    "PIMURUTAMAB": "PHASE_2_3",
    "PKI-166": "PHASE_2",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "RINDOPEPIMUT": "PHASE_3",
    "ROCILETINIB": "APPROVAL",
    "RUSERONTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "SIMOTINIB": "PHASE_1",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "THELIATINIB": "PHASE_1",
    "TOMUZOTUXIMAB": "PHASE_2",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZALUTUMUMAB": "PHASE_3"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "AMIVANTAMAB",
    "AUMOLERTINIB",
    "BRIGATINIB",
    "CETUXIMAB",
    "CETUXIMAB SAROTALOCAN",
    "DACOMITINIB",
    "ERLOTINIB",
    "GEFITINIB",
    "ICOTINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "LAZERTINIB",
    "MOBOCERTINIB",
    "NECITUMUMAB",
    "NERATINIB",
    "NIMOTUZUMAB",
    "OLMUTINIB",
    "OSIMERTINIB",
    "PANITUMUMAB",
    "ROCILETINIB",
    "VANDETANIB"
   ],
   "n_approved": 23,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "AUMOLERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "BRIGATINIB": [
     "non-small cell lung carcinoma",
     "anaplastic large cell lymphoma"
    ],
    "CETUXIMAB": [
     "malignant tumor of neck",
     "squamous cell carcinoma",
     "colorectal adenocarcinoma",
     "colorectal carcinoma",
     "colorectal cancer",
     "head and neck neoplasm",
     "colorectal neoplasm"
    ],
    "CETUXIMAB SAROTALOCAN": [
     "head and neck cancer"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "ERLOTINIB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ],
    "GEFITINIB": [
     "non-small cell lung carcinoma",
     "head and neck squamous cell carcinoma"
    ],
    "ICOTINIB": [],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "LAZERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "MOBOCERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "NECITUMUMAB": [
     "non-small cell lung carcinoma",
     "colorectal cancer",
     "non-small cell squamous lung carcinoma"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "NIMOTUZUMAB": [
     "head and neck cancer"
    ],
    "OLMUTINIB": [],
    "OSIMERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "PANITUMUMAB": [
     "colorectal cancer",
     "colorectal adenocarcinoma",
     "colorectal neoplasm"
    ],
    "ROCILETINIB": [],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CD274",
   "ensembl": "ENSG00000120217",
   "n_drug_entries": 13,
   "n_distinct_drugs": 13,
   "drugs": {
    "ADEBRELIMAB": "PHASE_3",
    "ATEZOLIZUMAB": "APPROVAL",
    "AVELUMAB": "APPROVAL",
    "BINTRAFUSP ALFA": "PHASE_3",
    "COSIBELIMAB": "APPROVAL",
    "DANBURSTOTUG": "PHASE_2",
    "DURVALUMAB": "APPROVAL",
    "ENVAFOLIMAB": "PHASE_3",
    "ERFONRILIMAB": "PHASE_3",
    "INCB-086550": "PHASE_2",
    "PACMILIMAB": "PHASE_2",
    "SOCAZOLIMAB": "PHASE_3",
    "SUGEMALIMAB": "APPROVAL"
   },
   "approved": [
    "ATEZOLIZUMAB",
    "AVELUMAB",
    "COSIBELIMAB",
    "DURVALUMAB",
    "SUGEMALIMAB"
   ],
   "n_approved": 5,
   "approved_for": {
    "ATEZOLIZUMAB": [
     "urothelial carcinoma",
     "non-small cell lung carcinoma",
     "breast cancer",
     "small cell lung carcinoma",
     "breast neoplasm",
     "transitional cell carcinoma"
    ],
    "AVELUMAB": [
     "Merkel cell skin cancer",
     "urothelial carcinoma",
     "neuroendocrine neoplasm"
    ],
    "COSIBELIMAB": [
     "head and neck squamous cell carcinoma"
    ],
    "DURVALUMAB": [
     "non-small cell lung carcinoma",
     "small cell lung carcinoma",
     "urothelial carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUGEMALIMAB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "PDCD1",
   "ensembl": "ENSG00000188389",
   "n_drug_entries": 26,
   "n_distinct_drugs": 26,
   "drugs": {
    "APL-501": "PHASE_2",
    "BALSTILIMAB": "PHASE_3",
    "BUDIGALIMAB": "PHASE_2_3",
    "CADONILIMAB": "PHASE_3",
    "CAMRELIZUMAB": "PHASE_3",
    "CEMIPLIMAB": "APPROVAL",
    "CETRELIMAB": "PHASE_3",
    "CS-1003": "PHASE_3",
    "DOSTARLIMAB": "APPROVAL",
    "FINOTONLIMAB": "PHASE_3",
    "LOMVASTOMIG": "PHASE_2",
    "NIVOLUMAB": "APPROVAL",
    "PEMBROLIZUMAB": "APPROVAL",
    "PENPULIMAB": "PHASE_3",
    "PIDILIZUMAB": "PHASE_2",
    "PIMIVALIMAB": "PHASE_2",
    "PUCOTENLIMAB": "PHASE_3",
    "RETIFANLIMAB": "APPROVAL",
    "SASANLIMAB": "PHASE_3",
    "SERPLULIMAB": "APPROVAL",
    "SINTILIMAB": "APPROVAL",
    "SPARTALIZUMAB": "PHASE_3",
    "TEBOTELIMAB": "PHASE_2_3",
    "TISLELIZUMAB": "APPROVAL",
    "TORIPALIMAB": "APPROVAL",
    "ZIMBERELIMAB": "PHASE_3"
   },
   "approved": [
    "CEMIPLIMAB",
    "DOSTARLIMAB",
    "NIVOLUMAB",
    "PEMBROLIZUMAB",
    "RETIFANLIMAB",
    "SERPLULIMAB",
    "SINTILIMAB",
    "TISLELIZUMAB",
    "TORIPALIMAB"
   ],
   "n_approved": 9,
   "approved_for": {
    "CEMIPLIMAB": [
     "squamous cell carcinoma",
     "basal cell carcinoma",
     "cutaneous squamous cell carcinoma",
     "cervical cancer"
    ],
    "DOSTARLIMAB": [
     "endometrial cancer",
     "endometrial neoplasm"
    ],
    "NIVOLUMAB": [
     "head and neck cancer",
     "pleural mesothelioma",
     "gastric cancer",
     "melanoma",
     "non-small cell lung carcinoma",
     "renal cell carcinoma",
     "transitional cell carcinoma",
     "colorectal neoplasm",
     "Hodgkins lymphoma",
     "mesothelioma",
     "head and neck squamous cell carcinoma",
     "classic Hodgkin lymphoma",
     "metastatic melanoma"
    ],
    "PEMBROLIZUMAB": [
     "melanoma",
     "metastatic melanoma",
     "endometrium neoplasm",
     "head and neck squamous cell carcinoma",
     "transitional cell carcinoma",
     "renal cell carcinoma",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma"
    ],
    "RETIFANLIMAB": [
     "neuroendocrine carcinoma",
     "Merkel cell skin cancer",
     "squamous cell carcinoma"
    ],
    "SERPLULIMAB": [
     "esophageal squamous cell carcinoma",
     "non-small cell lung carcinoma",
     "small cell lung carcinoma"
    ],
    "SINTILIMAB": [
     "Hodgkins lymphoma"
    ],
    "TISLELIZUMAB": [
     "esophageal cancer",
     "Hodgkins lymphoma",
     "non-small cell lung carcinoma",
     "adenocarcinoma",
     "esophageal squamous cell carcinoma",
     "gastric neoplasm"
    ],
    "TORIPALIMAB": [
     "melanoma",
     "nasopharyngeal carcinoma",
     "urothelial carcinoma",
     "esophageal squamous cell carcinoma",
     "Niemann-Pick disease type B"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "TERT",
   "ensembl": "ENSG00000164362",
   "n_drug_entries": 2,
   "n_distinct_drugs": 1,
   "drugs": {
    "IMETELSTAT": "APPROVAL"
   },
   "approved": [
    "IMETELSTAT"
   ],
   "n_approved": 1,
   "approved_for": {
    "IMETELSTAT": [
     "anemia",
     "myelodysplastic syndrome"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "FAT1",
   "ensembl": "ENSG00000083857",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "KMT2D",
   "ensembl": "ENSG00000167548",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "PTEN",
   "ensembl": "ENSG00000171862",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "PD-1": {
    "n": 17,
    "n_observational": 0,
    "n_active": 10,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05903833",
      "title": "Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy",
      "status": "RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05932212",
      "title": "AK104 for Recurrent or Metastatic Vulvar Cancer",
      "status": "RECRUITING",
      "last_update": "2025-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07290894",
      "title": "Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02379520",
      "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03220009",
      "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04084951",
      "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04357873",
      "title": "Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations",
      "status": "COMPLETED",
      "last_update": "2025-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430699",
      "title": "Cisplatin+Pembrolizumab+RT in Vulvar Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04708470",
      "title": "A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05357898",
      "title": "Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05761132",
      "title": "Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study",
      "status": "UNKNOWN",
      "last_update": "2023-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07101848",
      "title": "A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02379520",
       "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",
       "status": "COMPLETED",
       "last_update": "2026-04-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "nivolumab",
     "cemiplimab"
    ]
   },
   "PD-L1": {
    "n": 10,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05000294",
      "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260023",
      "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277482",
      "title": "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03439085",
      "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers",
      "status": "TERMINATED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03452332",
      "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04084951",
      "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04432597",
      "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949632",
      "title": "A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-L1",
     "atezolizumab",
     "durvalumab"
    ]
   },
   "EGFR": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06975410",
      "title": "Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00476476",
      "title": "Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar",
      "status": "COMPLETED",
      "last_update": "2015-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "EGFR",
     "cetuximab",
     "erlotinib"
    ]
   },
   "HPV E6/E7": {
    "n": 8,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05639972",
      "title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05686226",
      "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00019110",
      "title": "Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02379520",
      "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858310",
      "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers",
      "status": "COMPLETED",
      "last_update": "2026-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03180684",
      "title": "Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)",
      "status": "COMPLETED",
      "last_update": "2023-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03439085",
      "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers",
      "status": "TERMINATED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03937791",
      "title": "Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions",
      "status": "TERMINATED",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 5,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05639972",
       "title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",
       "status": "RECRUITING",
       "last_update": "2026-06-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05686226",
       "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",
       "status": "RECRUITING",
       "last_update": "2026-06-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02379520",
       "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",
       "status": "COMPLETED",
       "last_update": "2026-04-15",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02858310",
       "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers",
       "status": "COMPLETED",
       "last_update": "2026-03-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03937791",
       "title": "Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions",
       "status": "TERMINATED",
       "last_update": "2021-04-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "HPV E6",
     "HPV E7",
     "E6/E7",
     "ISA101",
     "VGX-3100"
    ]
   },
   "TROP2": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07804966",
      "title": "Sac-TMT in Vaginal and Vulvar Cancers",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "TROP2",
     "TACSTD2"
    ]
   },
   "CTLA-4": {
    "n": 6,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05932212",
      "title": "AK104 for Recurrent or Metastatic Vulvar Cancer",
      "status": "RECRUITING",
      "last_update": "2025-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03220009",
      "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03452332",
      "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04084951",
      "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab"
    ]
   }
  },
  "by_drug": {
   "ATEZOLIZUMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05000294",
      "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03074513",
      "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04084951",
      "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04432597",
      "title": "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AVELUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03260023",
      "title": "Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BINTRAFUSP ALFA": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04708470",
      "title": "A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CADONILIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05932212",
      "title": "AK104 for Recurrent or Metastatic Vulvar Cancer",
      "status": "RECRUITING",
      "last_update": "2025-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEMIPLIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07101848",
      "title": "A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DOSTARLIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06023862",
      "title": "A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)",
      "status": "RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DURVALUMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03277482",
      "title": "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03439085",
      "title": "DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers",
      "status": "TERMINATED",
      "last_update": "2024-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03452332",
      "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers",
      "status": "COMPLETED",
      "last_update": "2023-09-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ERLOTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00476476",
      "title": "Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar",
      "status": "COMPLETED",
      "last_update": "2015-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIVOLUMAB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02379520",
      "title": "HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03220009",
      "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",
      "status": "WITHDRAWN",
      "last_update": "2018-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04084951",
      "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEMBROLIZUMAB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05903833",
      "title": "Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy",
      "status": "RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07290894",
      "title": "Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01",
      "status": "RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02628067",
      "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04357873",
      "title": "Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations",
      "status": "COMPLETED",
      "last_update": "2025-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430699",
      "title": "Cisplatin+Pembrolizumab+RT in Vulvar Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05357898",
      "title": "Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05761132",
      "title": "Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study",
      "status": "UNKNOWN",
      "last_update": "2023-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SINTILIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07424664",
      "title": "A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZIMBERELIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07424664",
      "title": "A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}